Annals of Oncology 8:611-614, 1997
© 1997 European Society for Medical Oncology
other |
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
1Departments of Medical Oncology, Fox Chase Cancer Center Philadelphia, PA, USA
2Departments of Pharmacy, Fox Chase Cancer Center Philadelphia, PA, USA
3Departments of Nursing, Fox Chase Cancer Center Philadelphia, PA, USA
Correspondence to: Michael A. Bookman, MD Department of Medical Oncology Fox Chase Cancer Center 7701 Burholme Avenue Philadelphia, PA 19111, USA
PURPOSE: To estimate the incidence of hypersensitivity reactions using a short-course intravenous prophylactic regimen in patients receiving outpatient therapy with paclitaxel.
PATIENTS AND METHODS: Patients were identified from a retrospective search of a computerized pharmacy database covering a two-year period from January 1994 through December 1995. Eligible outpatients received paclitaxel as a one- to three-hour infusion 30 minutes after intravenous dexamethasone (10 or 20 mg), diphenhydramine (50 mg), and cimetidine (300 mg) or ranitidine (50 mg). Charts from all patients were then manually reviewed to verify drug administration and to record any evidence of hypersensitivity reactions during the first two cycles of therapy.
RESULTS: A total of 283 outpatients were identified from the pharmacy database and all charts reviewed. All patients received intravenous dexamethasone (5 to 20 mg) 30 minutes prior to paclitaxel without prior oral dexamethasone. Hypersensitivity reactions were documented in 13 patients (4.6%) during the first or second cycle with a 95% confidence interval (CI) of 2.2% to 7.0%. Reactions resolved rapidly without sequelae and did not require hospitalization. Only two reactions (0.7%) were graded as serious with a 95% CI of 0.2% to 1.2%, based on the use of bronchodilators and presence of angioedema. Therapy was continued with modification in 10 patients without recurrent hypersensitivity reaction. Therapy was discontinued in two patients without rechallenge and discontinued in one patient after rechallenge with a recurrent hypersensitivity reaction.
CONCLUSIONS: A short-course single-dose regimen of intravenous dexamethasone, diphenhydramine, and cimetidine (or ranitidine) offers a safe and convenient alternative for prevention of hypersensitivity reactions associated with outpatient paclitaxel administration.
Cremophor, dexamethasone, hypersensitivity, paclitaxel
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Maemondo, N. Masuda, I. Sekine, K. Kubota, Y. Segawa, M. Shibuya, F. Imamura, N. Katakami, T. Hida, S. Takeo, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy Ann. Onc., November 1, 2009; 20(11): 1860 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Segawa, K. Aogi, K. Inoue, M. Sano, I. Sekine, Y. Tokuda, H. Isobe, T. Ogura, M. Tsuboi, S. Atagi, et al. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy Ann. Onc., November 1, 2009; 20(11): 1874 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K. D. DILANA, E. M. KARAPANAGIOTOU, and K. N. SYRIGOS Therapy-induced Toxicity of the Lungs: An Overview Anticancer Res, February 1, 2009; 29(2): 631 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Harries, P. Ellis, and P. Harper Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer J. Clin. Oncol., November 1, 2005; 23(31): 7768 - 7771. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Itoh, T. Sendo, T. Hirakawa, T. Goromaru, S. Takasaki, H. Yahata, H. Nakano, and R. Oishi Role of Sensory Nerve Peptides Rather than Mast Cell Histamine in Paclitaxel Hypersensitivity Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Watanabe, N. Yamamoto, T. Tamura, T. Shimoyama, K. Hotta, A. Inoue, M. Sawada, Y. Akiyama, H. Kusaba, H. Nokihara, et al. Study of Paclitaxel and Dose Escalation of Cisplatin in Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2003; 33(12): 626 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Advani, G. A. Fisher, B. L. Lum, C. Jambalos, C. D. Cho, M. Cohen, A. Gollerkeri, and B. I. Sikic Phase I and Pharmacokinetic Study of BMS-188797, a New Taxane Analog, Administered on a Weekly Schedule in Patients with Advanced Malignancies Clin. Cancer Res., November 1, 2003; 9(14): 5187 - 5194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Ozols, B. N. Bundy, B. E. Greer, J. M. Fowler, D. Clarke-Pearson, R. A. Burger, R. S. Mannel, K. DeGeest, E. M. Hartenbach, and R. Baergen Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., September 1, 2003; 21(17): 3194 - 3200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sato, K. Inoue, T. Saito, T. Kai, H. Mihara, K. Okubo, J. Koh, H. Mochizuki, and T. Tabei Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01) Jpn. J. Clin. Oncol., August 1, 2003; 33(8): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gilbar and A. Ridge Dexamethasone prophylaxis for paclitaxel hypersensitivity Journal of Oncology Pharmacy Practice, June 1, 2002; 8(2-3): 81 - 87. [Abstract] [PDF]
|
|
|
|
|
|
Y. Akiyama, Y. Ohe, T. Tamura, M. Sawada, A. Inoue, H. Kusaba, N. Yamamoto, I. Sekine, H. Kunitoh, T. Kodama, et al. A Dose Escalation Study of Paclitaxel and Carboplatin in Untreated Japanese Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 482 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ota, T. Sugiyama, K. Komai, N. Hirai, S. Kumagai, K. Ushijima, T. Nishida, and T. Kamura Weekly 1 Hour Paclitaxel Infusion in Patients with Recurrent Gynecological Tumors: a Pilot Study Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 395 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hidalgo, C. Aylesworth, L. A. Hammond, C. D. Britten, G. Weiss, J. Stephenson Jr, G. Schwartz, A. Patnaik, L. Smith, K. Molpus, et al. Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel J. Clin. Oncol., May 1, 2001; 19(9): 2493 - 2503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Schilder, J. M. Gallo, M. M. Millenson, M. A. Bookman, L. M. Weiner, A. Rogatko, B. Rogers, K. Padavic-Shallers, M. Boente, N. Rosenblum, et al. Phase I Trial of Multiple Cycles of High-Dose Carboplatin, Paclitaxel, and Topotecan With Peripheral-Blood Stem-Cell Support as Front-Line Therapy J. Clin. Oncol., February 15, 2001; 19(4): 1183 - 1194. [Abstract] [Full Text] [PDF]
|
|